On Jan. 3, 2025, the Centers for Disease Control and Prevention (CDC) reported that during Christmas week, respiratory…
On Dec. 23, 2024, an Annenberg Public Policy Center (APPC) health survey conducted in November 2024 showed that…
On Dec. 16, 2024, JAMA Network Open published a study demonstrating respiratory syncytial virus (RSV) vaccine effectiveness in adults…
On Dec. 16, 2024, a study published in BMC Cardiovascular Disorders shows that pediatric and young adult COVID-19…
On Nov. 21, 2024, the U.S. Centers for Disease Control and Prevention (CDC) reported that by the week…
On Nov. 13, 2024, a study published in JAMA Network Open showed that respiratory syncytial virus (RSV) was…
On Nov. 5, 2024, a World Health Organization (WHO) study published in eBioMedicine named 17 pathogens that regularly…
On Oct. 22, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO® (Respiratory…
On Sept. 19, 2024, a U.S. population-based birth cohort study was released that showed that 53.4% of babies…
On Sep. 4, 2024, researcher led by the Centers for Disease Control and Prevention (CDC) and Vanderbilt University…
On Aug. 28, 2024, survey data from the Annenberg Public Policy Center (APPC) found that the number of…
On Jul. 8, 2024, a study reported that babies exposed to maternal RSV (respiratory syncytial virus) vaccination in…
On Jun. 10, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use…
On May 31, 2024, Moderna announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345),…
On Jan. 4, 2024, AstraZeneca Sanofiﾒs Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…
On Nov. 23, 2023, the World Health Organization (WHO) announced that it was monitoring data from Chinese surveillance…
On Nov. 16, 2023, the CDC announced the release of more than 77,000 additional doses of Beyfortusﾙ (nirsevimab-alip…
On Nov. 6, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was conducting…
On Aug. 21, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
On Aug. 1, 2023, BD announced that the U.S. Food and Drug Administration (FDA) 510(k) had provided clearance…
On Jul. 17, 2023, the FDA approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…
On Jun. 29, 2023, the Centers for Disease Control and Prevention (CDC) endorsed the CDC Advisory Committee on…
On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
On May 3, 2023, the U.S. FDA approved GlaxoSmithKline’s Arexvy as the first respiratory syncytial virus (RSV) vaccine…
On Apr. 27, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
On Dec. 21, 2022, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic…
On Dec. 7, 2022, Pfizer announced that the U.S. Food and Drug Administration (FDA) had accepted for priority…